Objective: The aim of this study was to compare outcomes after rapiddeployment aortic valve replacement (RDAVR) and conventional aortic valve replacement (AVR) from two studies. Methods: Patients who underwent RDAVR (INTUITY valve) in the prospective, 5-year, single-arm multicenter TRITON study, or conventional AVR (Perimount Magna Ease valve) in the prospective Perimount Magna Ease postmarket study, were propensity score matched and compared for procedural, hemodynamic, safety, and clinical outcomes. Results: Matched RDAVR (n = 106) and conventional AVR (n = 106) patients had similar baseline characteristics (mean ± SD age, 72.8 ± 7.6 vs 72.5 ± 7.4 years; male 59.4% vs 61.3%) and procedures (concomitant procedures: 41.5% vs 50.9%). Mean ± SD aortic cross-clamp time was significantly shorter in RDAVR than AVR patients (51.8 ± 20.9 vs 73.9 ± 33.2 minutes; P < 0.001), as was mean cardiopulmonary bypass time (82.8 ± 34.2 vs 102.4 ± 41.7 minutes; P < 0.001). At 1 year, RDAVR patients showed significantly lower mean ± SD and peak aortic valve gradients (9.0 ± 3.4 and 17.0 ± 6.2 mm Hg, respectively) than conventional AVR patients (13.4 ± 5.5 and 24.2 ± 10.8 mm Hg, respectively; all P < 0.001). Patient-prosthesis mismatch was significantly less common with RDAVR than with AVR [overall: 16/66 (24.2%) vs 46/76 (60.5%); P = 0.007; severe: 2/66 (3.0%) vs 13/76 (17.1%)]. There were no significant differences between the RDAVR and AVR groups regarding 30-day safety endpoints. Survival rates in the RDAVR and conventional AVR groups were, respectively, 99.1% and 100.0% at 30 days, 97.1% and 95.1% at 1 year, and 93.3% and 94.1% at 3 years (P = nonsignificant). Conclusions: In this retrospective study with matched populations, the RDAVR with the INTUITY valve system provided superior procedural and hemodynamic outcomes than a standard bioprosthesis without compromising safety.
C onventional aortic valve replacement (AVR) for aortic valve stenosis in patients older than 65 years is traditionally performed with standard bioprostheses requiring several U-fashion stitches or running sutures for the anchoring to the annulus. The new bioprosthetic valves allowing rapid-deployment aortic valve replacement (RDAVR) offer the potential for shorter aortic cross-clamp time and cardiopulmonary bypass (CPB) time, with shorter ventilation time and a similar survival rate when compared with conventional AVR. [1] [2] [3] [4] [5] [6] [7] [8] Minimally invasive procedures for AVR (such as the partial upper ministernotomy or the right minithoracotomy) have been developed with the potential benefits of shortened intensive care unit and hospital stay, shorter ventilation time, and reduced blood loss. 9 However, the major drawback of these approaches is the longer cross-clamp time and CPB time due to the more complex surgical procedures. [9] [10] [11] [12] Therefore, an RDAVR valve may be the ideal partner in minimally invasive aortic valve surgery.
The Edwards INTUITY valve system (Edwards Lifesciences, Irvine, CA USA) is a balloon-expandable, stented, bovine, pericardial bioprosthesis based on the Edwards Perimount valve system (Edwards Lifesciences, Irvine, CA USA). [2] [3] [4] [5] [6] [7] 13, 14 A randomized controlled trial of minimally invasive RDAVR with INTUITY valves recently reported shorter cross-clamp time and improved hemodynamic function over 1 year versus conventional full sternotomy AVR. 6, 7 The aim of this study is to compare procedural, hemodynamic, safety, and midterm clinical outcomes (up to 3 years) of two matched populations operated for AVR with the INTUITY valve system and the standard Perimount Magna Ease valve.
METHODS

Study Design
This is a retrospective study comparing the outcome of patients operated for severe symptomatic aortic valve stenosis with RDAVR using the INTUITY valve system and included in the Surgical Treatment of Aortic Stenosis with an RDAVR Surgical Aortic Valve (TRITON) study with patients treated with conventional AVR using the Perimount Magna Ease valve included in a prospective postapproval study. Propensity scoring was used to generate two matched patient cohorts from these two studies.
Data Collection and Patients
TRITON (Clinicaltrials.gov NCT01445171) was a prospective, 5-year, single-arm, nonrandomized, multicenter trial conducted in Europe to evaluate the Edwards INTUITY valve (model 8300A or 8300AB), as previously described. [3] [4] [5] Briefly, recruited patients were male and female adults (aged ≥18 years) undergoing planned aortic valve surgery for aortic stenosis with or without aortic insufficiency, undertaken with or without concomitant procedures. Rapid-deployment aortic valve replacement was performed either through a minimal invasive access (upper ministernotomy or anterior right minithoracotomy) or through a full sternotomy, according to the surgeon's preference. Primary exclusion criteria included pure aortic insufficiency, concomitant valve disease requiring repair with an annuloplasty ring or replacement with prosthesis, left ventricular ejection fraction (LVEF) of less than 25%, true bicuspid aortic valve (ie, Sievers type 0), and myocardial infarction within 1 month or stroke within 6 months before the scheduled RDAVR. Clinical and echocardiographic follow-up data were collected at baseline, discharge, 3 months, and 12 months postoperatively and thereafter for 5 years. Hemodynamic assessments were made according to guidelines, 15 and all hemodynamic data were reviewed by an independent echocardiographic core laboratory (Columbia University Medical Center, New York, NY USA).
The Perimount Magna Ease postapproval study (ClinicalTrials. gov NCT01171625) was a prospective, single-arm, multicenter international study designed to assess the midterm safety and performance of the Perimount Magna Ease valve (model 3300TFX) in a postmarket, phase 4 setting. Based on the Carpentier-Edwards Perimount valve system, the Perimount Magna Ease valve is the conventional counterpart of the Edwards INTUITY valve. The Perimount Magna Ease valve has shown excellent clinical results and has been widely used. 16 The postmarketing study recruited male and female adults (aged ≥18 years) undergoing AVR with or without concomitant procedures. Patients were assessed at various time-points and signed informed consents. Both studies obtained respective institutional review board approvals before patient enrolment. 3, 16 Both studies also used guidelines for reporting mortality and morbidity after cardiac valve interventions. 17 
Statistical Analysis
This retrospective analysis included all patients in the TRITON and Perimount Magna Ease postapproval studies who completed 3 years of follow-up. The analysis used an "as treated" approach, that is, excluding patients implanted with valves other than the INTUITYor the Perimount Magna Ease.
Preoperative data were compared between the groups using the independent samples t test for continuous variables and Pearson χ 2 test for discrete variables. Propensity scores, calculated from baseline variables, were used to match patients in two subgroups. A multivariable logistic regression model including all 35 preoperative risk factors available within both groups was applied (Supplementary Table S1 , Supplemental Digital Content 1, http://links.lww.com/INNOV/A177). The C-statistic was 0.864, indicating good discrimination. Patient-to-patient matching was performed with the "Matching" library in the R Software (version 4. 8-3.4) 18 using the nearest-neighbor matching without replacement algorithm, with a default caliper of 0.05 times the standard deviation (SD) of the logit of the propensity scores.
The covariance balance was assessed by calculating standardized mean difference and performing paired t test and McNemar test for continuous and discrete variables, respectively. Further, pseudo R 2 of the logistic regression model decreased from 0.329 on whole population to 0.067 on matched population. This shows that risk factors do not explain the participation probability after matching.
Baseline characteristics and postimplantation outcomes common to both studies were compared between the matched groups using the paired samples t test and McNemar tests for continuous and discrete variables, respectively. The Wilcoxon signed-rank test was used to compare mean valve sizes, after matching. Performance outcomes compared were cross-clamp and CPB times and 1-year hemodynamic variables, namely, LVEF, mean and peak aortic gradients, effective orifice area (EOA) and EOA indexed to patient body surface area (EOAi), and patientprosthesis mismatch (PPM; measured using transthoracic echocardiography). Safety outcomes compared at 30 days after implantation included all-cause mortality, bleeding, major bleeding, endocarditis, valve explant, hemolysis, paravalvular leak, pacemaker implantation, structural and nonstructural valve deterioration, reoperation, thromboembolic event, valve thrombosis, cardiac failure, and renal, respiratory, and sternal wound complications. Two-sided tests were used throughout, and a type I error of 0.05 was considered significant. Kaplan-Meier survival curves for the two groups were compared using Cox regression, stratified by matched pairs. All analyses were performed using the R software (version 2.15.3). 19 All data are expressed as mean ± standard deviation (± SD) or as numbers and percentages (%).
RESULTS
Unmatched Group Characteristics
In the TRITON study, 287 of 295 patients enrolled in six centers in Germany and Austria between January 2010 and October 2012 received the Edwards INTUITY valve and completed a mean ± SD follow-up time of 2.7 ± 0.8 years. In the Perimount Magna Ease postapproval study, 258 patients were implanted with this valve between October 2007 and February 2013 and completed 3 years of follow-up. These populations were the basis for this analysis.
Before matching, patients in the RDAVR group (n = 287) were significantly older, more likely to be female, and generally sicker than patients in the conventional AVR group (n = 258) ( Table 1) . Rapid-deployment aortic valve replacement patients had more severe heart failure and were more likely to have chronic renal failure, hypertension, arrhythmias (all P < 0.001), and diabetes (P = 0.036). Rapid-deployment aortic valve replacement patients also showed more concomitant mitral and tricuspid regurgitation than AVR patients (P < 0.001) and were more likely to have a pacemaker already implanted before surgery (P = 0.005).
Similar proportions of patients in the RDAVR and conventional AVR groups underwent isolated AVR (55.1% and 55.8%, respectively), AVR plus coronary artery bypass grafting (CABG) (27.2% and 19.8%), AVR plus a non-CABG procedure (13.2% and 16.7%), or AVR plus CABG and at least one additional procedure (4.5% and 7.8%). The mean ± SD implanted valve size was 23.1 ± 1.9 mm in the RDAVR group and 23.7 ± 2.2 mm in the conventional AVR group (P < 0.001).
Before matching, the mean ± SD propensity score was 0.72 ± 0.24 in the RDAVR group (n = 282; data missing for 5 patients) and 0.32 ± 0.25 in the conventional AVR group (n = 252; data missing for 6 patients).
Matched Group Characteristics
Propensity score matching resulted in two similar groups, each comprising 106 patients. The mean ± SD propensity scores for the matched RDAVR and conventional AVR groups were 0.52 ± 0.23 and 0.52 ± 0.23, respectively.
The matched RDAVR and conventional AVR groups showed similar baseline characteristics, as shown by standardized mean differences of less than 0.1 for most variables (Table 1 ). In addition, there is no significant difference in risk factors between the two groups as tested by paired t test and McNemar test, respectively. Similar proportions of matched RDAVR and conventional AVR patients underwent isolated AVR (58.5% vs 49.1%, respectively), AVR plus CABG (27.4% and 27.4%), AVR and a non-CABG procedure (10.4% and 15.1%), or AVR plus CABG and at least one additional procedure (3.8% and 8.5%). The mean implanted valve size was 23.4 ± 1.8 mm in the RDAVR group and 23.0 ± 2.3 mm in the conventional AVR group (P = 0.217). The remaining results refer exclusively to the matched groups.
Procedural Outcomes
Mean ± SD aortic cross-clamp time was significantly shorter in the matched RDAVR group (51.8 ± 20.9 minutes) than in the AVR group (73.9 ± 33.2 minutes; P < 0.001), as was the CPB time (82.8 ± 34.2 minutes vs 102.4 ± 41.7 minutes; P < 0.001). Cross-clamp and CPB times were significantly shorter in the RDAVR group versus the conventional AVR cohorts also in the largest subgroups of patients undergoing isolated AVR and AVR plus CABG ( Table 2) .
The distribution of the surgical approach for the INTUITY arm after matching was full sternotomy 75.5% (80/106), miniupper sternotomy 19.8% (21/106), and right thoracotomy 4.7% (5/106). Please note that surgical approach data are not available for Magna Ease arm.
Valve Hemodynamic Performance at Follow-up
At 1-year follow-up, patients who underwent RDAVR showed lower mean ± SD and peak valve gradients (9.0 ± 3.4 mm Hg and 17.0 ± 6.2 mm Hg, respectively) than those who underwent conventional AVR (13.4 ± 5.5 mm Hg and 24.2 ± 10.8 mm Hg, respectively; P < 0.001 for both comparisons) ( Table 3 ). Mean and peak gradients were significantly lower in the RDAVR cohort for patient subgroups implanted with 21-, 23-, and 25-mm valves. The same pattern of results was seen in the 19 mm and 27 mm subgroups, although statistical significance was not achieved in these small groups (Supplementary Tables S2-S6 statistical significance in the largest 23-mm valve subgroup: moderate PPM occurred in 3/27 (11.1%) of these RDAVR patients (no severe episodes), whereas in the conventional AVR subgroup there were 13 patients (46.4%) with moderate PPM and 5 patients (17.9%) with severe PPM (overall P < 0.001).
Left ventricular ejection fraction did not differ significantly between the groups.
Clinical Safety Outcomes
The matched RDAVR and conventional AVR groups did not differ significantly with respect to 30-day safety endpoints (Table 4) or 3-year Kaplan-Meier survival curves (Fig. 1) . This was the case for patients in each subgroup categorized by the procedure type, that is, isolated AVR, AVR plus CABG, AVR plus non-CABG, and AVR plus CABG and another procedure (Supplementary Tables  S7-S10 , Supplemental Digital Content 3, http://links.lww.com/ INNOV/A191). It should be noted that RDAVR group did have numerically higher numbers of patients with major bleeding, major paravalvular leak, permanent pacemaker implantations, and acute kidney failure (Table 4 ). Estimated survival rates in the RDAVR and conventional AVR groups were, respectively, 99.1% vs 100.0% at 30 days, 97.1% vs 95.1% at 1 year, 93.3% vs 95.1%, at 2 years, and 93.3% vs 94.1% at 3 years (Fig. 1) .
DISCUSSION
This propensity-matched analysis showed that patients who underwent RDAVR with the INTUITY valve system had significantly shorter aortic cross-clamp and CPB times, lower mean and peak aortic valve gradients, lower risk of moderate or severe PPM, and similar safety and survival rates over 3 years, as compared with patients who underwent conventional AVR with standard Perimount valves. Although this was a retrospective analysis, propensity score matching rendered two well-matched cohorts of patients that did not differ significantly according to a battery of preoperative variables and which were therefore suitable for comparison. Propensity score matching is a powerful statistical tool to strengthen causal inferences drawn from retrospective studies and to ensure that only similar patients are selected. It is increasingly used and accepted in the literature, most notably for medical devices where randomized controlled *See Kocher et al 3 for details. †The reasons for reoperation were specified as moderate paravalvular leak (n = 1) and bleeding-hemolysis (n = 1) in the RDAVR group and "other, not specified" in the AVR group (n = 1).
AVR, aortic valve replacement; NA, not applicable; RDAVR, rapid deployment AVR. trials are more challenging to perform and real-world evidence can be more powerful. 20, 21 These results add to a growing body of evidence suggesting that RDAVR offers procedural benefits and improved hemodynamics compared with conventional aortic bioprostheses. Experts have recently recommended that sutureless and rapid deployment valves should be considered as the prosthesis of choice for isolated aortic valve procedures in patients with comorbidities, in the elderly, and in certain other circumstances such as complex concomitant procedures requiring longer surgical time. 22 The aortic cross clamp time and CPB time are predictors of mortality, morbidity, and length of hospital stay in patients undergoing AVR. [10] [11] [12] The procedural times for conventional AVR in the present analysis are consistent with reported ranges in the available literature. 2, [23] [24] [25] In this analysis, RDAVR was associated with significantly reduced cross-clamp and CPB times overall and, in particular, in the subgroups who underwent AVR only or AVR plus CABG. A systematic review of 11 studies using three different valve products recently concluded that RDAVR was invariably associated with shorter aortic cross-clamp times than conventional AVR (30-56 minutes vs 49-88 minutes). 1 Most of these studies were cohort studies, but the findings were confirmed by the prospective, randomized, multicenter CADENCE-MIS study. CADENCE-MIS compared minimal invasive RDAVR (using the INTUITY aortic valve system without concomitant procedures; n = 46) versus AVR via full sternotomy using a conventional stented valve of the investigator's preference (n = 48). 6, 7 Minimal invasive RDAVR was associated with significantly reduced cross-clamp times compared with conventional AVR (41.3 ± 20.3 minutes vs 54.0 ± 20.3 minutes; P < 0.001), although CPB time was not significantly shortened. Supporting results were also provided by a single-center, parallel cohort study that compared RDAVR with the INTUITY valve (n = 116) versus conventional AVR with Perimount Magna Ease (n = 132). 2 Patients were neither randomized nor matched in this study, and the mean ± SD valve size was significantly higher in the conventional AVR group than RDAVR group (23.2 ± 2.0 mm vs 22.5 ± 2.2 mm; P = 0.007). Minimal invasive procedures were significantly more common among patients implanted with the RDAVR valve than conventional valve (59% vs 39%; P < 0.001) and, although cross-clamp times were similar between the groups overall, RDAVR was associated with reduced cross-clamp time, perfusion, and procedural times versus conventional AVR in patients who underwent full sternotomy. 2 Recently, a propensitymatched, single-center study (n = 41 pairs) also confirmed that RDAVR was associated with significantly shorter cross-clamp time (71 ± 33 minutes vs 106 ± 42 minutes; P < 0.01) and CPB times (95 ± 42 minutes vs 134 ± 47 minutes; P < 0.01) than conventional AVR, when both types of prosthesis were implanted through a full sternotomy. 8 In this analysis, RDAVR was also associated with significantly lower rates of moderate and severe PPM at 1 year versus conventional AVR, together with lower mean and peak transvalvular gradients.
Patient-prosthesis mismatch occurs when the EOA of the bioprosthesis is too small compared with the patient's body size, causing a high transvalvular gradient and lower long-term survival. [26] [27] [28] Our findings are consistent with previously reported studies. In the CADENCE-MIS, minimal invasive RDAVR patients also had significantly lower peak gradients after 1 year, with a trend toward lower mean gradients, and a significantly greater EOA compared with the control group. 7 In the aforementioned parallel cohort study, 2 the subgroup analysis of the most common valve sizes (21 mm and 23 mm; implanted in 64% of patients) also showed significantly lower mean postoperative transvalvular gradients in the RDAVR group than the conventional AVR group. Moreover, the aforementioned multiproduct systematic review reported benefits of RDAVR on postoperative bleeding, blood transfusion requirements, ventilation time, and renal injury. 1 Another recent propensity-matched, single-center study (n = 41 pairs) showed significant benefits of RDAVR over conventional AVR on mean ± SD ventilation time (17 ± 25 hours vs 63 ± 131 hours; P < 0.01), intensive care unit stay (51 ± 45 hours vs 108 ± 157 hours; P = 0.03), and new onset of postoperative atrial fibrillation/flutter (8% vs 20%; P = 0.02). 8 In the present analysis, we found no significant differences between the matched RDAVR and conventional AVR groups with respect to safety endpoints assessed at 30 days postimplant, including new permanent pacemaker implantation. The 3-year Kaplan-Meier survival rates were also good and similar between the cohorts. These data support previous evidence that mortality rates with RDAVR are similar to those with conventional AVR. 1, 2, 7, 8 Further real-world evidence regarding longer-term outcomes after RDAVR is awaited from ongoing registry studies. 29, 30 There are some limitations with this study; this was a retrospective analysis of data over a 6-year period from two separate studies with differing protocols and available datasets. Studies of this type are inherently subject to a significant risk of bias, including allocation bias associated with surgeon preference and classification bias arising from data collection and recording. Therefore, the propensity score matching was used to create comparable cohorts from these studies. Although the matched cohorts did not differ significantly according to available data, the potential for additional, untested confounding variables to introduce bias cannot be fully excluded. The analysis was also limited to the outcomes variables for which data were available, at common timepoints, from both studies. Pertinent data that may have been informative, but which were unavailable from at least one study, included the surgical approach and the left ventricular mass regression. This study was specifically designed to compare cohorts implanted with the INTUITY and the Perimount Magna Ease valve and therefore rates of conversion from the INTUITY valve to conventional valve (eg, because of severe paravalvular leak) were not analyzed. However, there were no significant differences in paravalvular leak rates between the two cohorts. Finally, our analysis was limited to 3-year follow-up and a longer follow-up might be necessary to unmask potential survival benefit with the RDAVR valve.
In conclusion, in this multicentric, retrospective analysis of matched populations, the RDAVR using the INTUITY valve system provided superior procedural and hemodynamic outcomes compared with the conventional AVR with the Perimount Magna Ease valve, without compromising safety.
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